3D Medicines, Inc. (1244) AI Stock Analysis

• Market Cap: HK$1.63B
• Dividend Yield: N/A
• Average Volume (3M): 316.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.53
• Revenue Growth: -8.43%
• EPS Growth: 64.33%
• Country: HK
• Employees: 191
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.39
• Shares Outstanding: 258,177,000
• 10 Day Avg. Volume: 146,150
• 30 Day Avg. Volume: 316,957
• PEG Ratio: 0.06
• Price to Book (P/B): 0.89
• Price to Sales (P/S): 1.56
• P/FCF Ratio: -2.78
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: HK$6.00 ▼(-2.28% Downside)

The overall stock score is primarily influenced by financial performance challenges, including negative profitability and reliance on external funding. Technical analysis suggests a bearish trend but indicates potential for a rebound due to oversold conditions. Valuation is a concern due to the negative P/E ratio and lack of dividend yield.

3D Medicines, Inc. Business Overview & Revenue Model

Company Description

3D Medicines, Inc. is a biotechnology company focused on developing advanced therapies in the field of precision medicine with a particular emphasis on oncology. The company operates in the pharmaceutical sector, concentrating on the research, development, and commercialization of innovative treatments tailored to individual patient needs. Its core products include a portfolio of targeted therapies and diagnostic tools designed to improve treatment outcomes for cancer patients.

How the Company Makes Money

3D Medicines, Inc. generates revenue primarily through the sale of its pharmaceutical products and therapies, which are marketed to healthcare providers and institutions. The company may also derive income from licensing agreements with other pharmaceutical companies, allowing them to use its proprietary technologies or compounds. Additionally, strategic partnerships with research institutions and collaboration agreements can contribute to its revenue by providing funding for ongoing clinical trials and development projects. Government grants and funding for innovative healthcare solutions may also play a role in supporting the company's financial growth.

3D Medicines, Inc. Financial Statement Overview

Summary

3D Medicines, Inc. is experiencing substantial revenue growth but continues to face profitability challenges. Operational inefficiencies are evident in negative margins, and the company relies heavily on external financing. The balance sheet shows improvement, but cash flow issues persist.

Income Statement

The company shows significant revenue growth from 2020 to 2024, with a strong increase in total revenue. However, the net income remains negative, indicating persistent losses. Gross profit margin is high, but negative EBIT and EBITDA margins highlight operational inefficiencies.

Balance Sheet

The balance sheet shows a strong cash position with substantial cash equivalents and short-term investments. However, the company has a negative equity position until 2022, which improved in later years. The debt-to-equity ratio is concerning due to high leverage in earlier years, but it has improved recently.

Cash Flow

Operating cash flow has been negative, showing challenges in generating cash from core operations. Free cash flow is consistently negative, reflecting high capital expenditures and operational challenges. Financing cash flow is positive, indicating reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	448.39M	445.65M	634.95M	567.39M	60.26M	0.00
Gross Profit	373.68M	371.74M	524.01M	525.18M	55.98M	0.00
EBITDA	-199.91M	-226.95M	-529.23M	-1.03B	-1.45B	-303.35M
Net Income	-168.50M	-182.66M	-524.70M	-1.02B	-1.43B	-635.38M
Balance Sheet
Total Assets	1.14B	1.22B	1.43B	1.33B	1.06B	496.22M
Cash, Cash Equivalents and Short-Term Investments	447.10M	840.98M	996.58M	942.03M	824.48M	414.26M
Total Debt	162.97M	237.62M	282.43M	175.70M	58.74M	1.67B
Total Liabilities	509.91M	512.54M	558.20M	436.65M	3.33B	1.77B
Stockholders Equity	716.15M	785.06M	936.74M	943.00M	-2.24B	-1.27B
Cash Flow
Free Cash Flow	-55.38M	-249.60M	-150.74M	-332.76M	-433.46M	-289.48M
Operating Cash Flow	-48.66M	-210.58M	-144.41M	-278.78M	-377.08M	-278.33M
Investing Cash Flow	-91.12M	17.95M	-187.58M	-242.11M	-98.87M	-20.48M
Financing Cash Flow	-100.33M	-33.92M	304.51M	408.41M	840.08M	607.39M

3D Medicines, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1244, the sentiment is Negative. The current price of 6.14 is below the 20-day moving average (MA) of 6.74, below the 50-day MA of 7.53, and above the 200-day MA of 5.03, indicating a neutral trend. The MACD of -0.38 indicates Negative momentum. The RSI at 39.62 is Neutral, neither overbought nor oversold. The STOCH value of 35.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1244.

3D Medicines, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	―	HK$1.54B	189.52	0.99%	―	9.41%	-32.69%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
6998	―	HK$1.56B	66.67	2.04%	―	1447.56%	―
2137	―	€1.39B	―	-14.48%	―	―	-41.48%
1244	―	HK$1.63B	―	-21.45%	―	-8.43%	64.33%
6628	―	HK$1.35B	-4.32	-34.18%	―	-57.84%	24.58%
2126	―	HK$1.57B	―	-51.56%	―	2.45%	2.58%

3D Medicines, Inc. Corporate Events

3D Medicines Reports Strong Progress and Global Expansion in H1 2025

3D Medicines Inc. reported significant progress in the first half of 2025, leveraging a recovering biotech-focused capital market in Hong Kong. The company achieved stable revenue and met key R&D milestones, with notable advancements in the commercialization of Envafolimab, its first commercialized product, which saw a 1.3% increase in sales revenue in China. The company presented multiple research achievements at the 2025 ASCO Annual Meeting, highlighting the efficacy and safety of Envafolimab in various cancer treatments. These developments underscore 3D Medicines’ commitment to innovation-driven growth and global expansion, marking a new chapter in its operational strategy.

The most recent analyst rating on (HK:1244) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on 3D Medicines, Inc. stock, see the HK:1244 Stock Forecast page.

3D Medicines Administers First Dose of Novel Cancer Drug

3D Medicines Inc. has successfully administered the first dose of its novel radioactive drug conjugate, 3D1015, in a human trial. This study aims to evaluate the safety and preliminary efficacy of the drug in patients with PSMA-positive metastatic castration-resistant prostate cancer, a group with significant unmet clinical needs. The trial will provide critical clinical evidence for dosage determination and risk management in future clinical trials, potentially impacting the company’s operations and positioning in the oncology drug development market.

The most recent analyst rating on (HK:1244) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on 3D Medicines, Inc. stock, see the HK:1244 Stock Forecast page.

3D Medicines Partners with CATUG Biotechnology to Enhance mRNA Therapy Development

3D Medicines Inc. has entered into a strategic cooperation agreement with CATUG Biotechnology to advance the development of TLNP-delivered in vivo CAR-T/NK therapies. This collaboration aims to combine 3D Medicines’ mRNA R&D platform and LNP delivery system with CATUG’s expertise in large-scale mRNA production, enhancing the company’s capabilities in targeted LNP delivery, cancer vaccines, and immune cell therapies. The agreement is expected to accelerate 3D Medicines’ expansion in mRNA research and support the clinical development and commercialization of its innovative therapeutic products.

The most recent analyst rating on (HK:1244) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on 3D Medicines, Inc. stock, see the HK:1244 Stock Forecast page.

3D Medicines Inc. Schedules Board Meeting for Interim Results and Dividend Consideration

3D Medicines Inc. has announced that its board of directors will meet on August 29, 2025, to approve the unaudited interim results for the first half of the year and discuss the potential payment of an interim dividend. This meeting is significant as it will provide insights into the company’s financial performance and potential shareholder returns, impacting its market positioning and investor relations.